Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boostrix, Adacel Tdap Boosters Are Effective, FDA Advisory Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory panel members urge postmarket monitoring for GSK and Sanofi Pasteur boosters in patients who received full series of acellular pertussis vaccines as children, given that the studies were conducted in patients who received whole-cell vaccines. Committee endorses “effectiveness,” but offers no opinion on “efficacy.”

You may also be interested in...



Teen Vaccine Approvals Increasing, FDA Says

The agency is observing a rise in the number of vaccines targeted at adolescents, CBER Vaccine Research & Review Director Baylor says. Two vaccines for use in adolescents – Menactra and Boostrix – have been approved so far this year; a third, Adacel, has a user fee date of June 11.

Teen Vaccine Approvals Increasing, FDA Says

The agency is observing a rise in the number of vaccines targeted at adolescents, CBER Vaccine Research & Review Director Baylor says. Two vaccines for use in adolescents – Menactra and Boostrix – have been approved so far this year; a third, Adacel, has a user fee date of June 11.

GSK May Launch Boostrix Vaccine Ahead Of June CDC Recommendation

The tetanus, diphtheria and pertussis vaccine clears FDA for patients ages 10 through 18. The vaccine approval follows the advisory committee's 13-0 unanimous recommendation in favor of use in that population, as well as its recommendation for a postmarketing trial.

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel